GlassScriptPhysician profile
Rachael Sanchez
NPI 1790915064
$12,022.05
in general payments reported to CMS, 2019-2025
42 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Addiction Medicine (Family Medicine) provider received nationally (typical 2025 total: $143).
See the full distribution for Addiction Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $534 · 2021: $4,796 · 2022: $2,115 · 2023: $2,352 · 2024: $1,551 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,074.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,213.18 | 2021-2024 | Qulipta, Ubrelvy, Botox |
| Biohaven Pharmaceuticals, INC. | $1,906.35 | 2020-2021 | |
| Amgen INC. | $1,064.95 | 2019-2024 | Otezla, Enbrel |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $733.67 | 2020-2024 | Relistor |
| Collegium Pharmaceutical, INC. | $632.34 | 2020-2024 | Xtampza, Belbuca |
| Lundbeck LLC | $479.36 | 2020-2024 | Vyepti |
| Medtronic, INC. | $433.51 | 2021-2024 | Intellis Adaptivestim |
| Braeburn INC. | $414.56 | 2023-2024 | Brixadi |
| Indivior INC. | $410.92 | 2019-2024 | Sublocade |
| Boston Scientific Corporation | $364.66 | 2019-2023 | Superion Indirect Decompression System, Wavewriter Alpha Prime 16 |
| Biodelivery Sciences International, INC. | $321.03 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $264.10 | 2022 | |
| Pfizer INC. | $257.70 | 2021-2024 | |
| Vertos Medical, INC. | $228.64 | 2021-2023 | Mild Device Kit |
| Lilly USA, LLC | $207.94 | 2019-2023 | Reyvow, Emgality |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $206.04 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $201.12 | 2023-2024 | Quviviq |
| Abbott Laboratories | $174.32 | 2021-2023 | Proclaim |
| Axsome Therapeutics, INC. | $171.64 | 2025 | Auvelity |
| Novo Nordisk INC | $151.16 | 2019 | |
| Upsher-Smith Laboratories LLC | $140.78 | 2020-2023 | |
| Teva Pharmaceuticals USA, INC. | $138.79 | 2020-2021 | |
| Spr Therapeutics, INC | $116.91 | 2023 | Sprint Pns System |
| Abiomed | $111.42 | 2019 | |
| Redhill Biopharma INC. | $82.58 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $76.55 | 2022-2023 | Euflexxa |
| Horizon Therapeutics Plc | $72.73 | 2021-2022 | |
| Orexo US, INC. | $58.77 | 2021-2023 | Zubsolv |
| Novartis Pharmaceuticals Corporation | $58.25 | 2020-2021 | |
| Ucb, INC. | $50.67 | 2022 | |
| Alkermes, INC. | $42.52 | 2020-2023 | Vivitrol |
| Amneal Pharmaceuticals LLC | $37.45 | 2023 | Lyvispah |
| Masimo Corporation | $30.53 | 2023 | Bridge |
| Depuy Synthes Sales INC. | $27.32 | 2023 | Monovisc, Orthovisc |
| Protega Pharmaceutials INC | $22.07 | 2023 | Roxybond |
| Mdd US Operations, LLC | $20.10 | 2020 | |
| Valinor Pharma, LLC | $19.11 | 2024 | Movantik |
| Forte Bio-Pharma LLC | $18.45 | 2024 | Prolate, Nalocet |
| Gilead Sciences, INC. | $16.22 | 2021 | |
| Nalu Medical, INC. | $15.34 | 2021 | |
| Pear Therapeutics (US), INC. | $14.55 | 2022 | |
| Apollo Endosurgery US INC | $13.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachael Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.